開示資料
2020/01/24
Joint Research with View to Developing Regenerative Medicine Product for Type 1 Diabetes2019/12/25
- [Delayed]Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
2019/12/25
- [Delayed]Q&A
2019/12/16
- Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
2019/12/16
- 2019年12月13日付け第３四半期決算短信及び再生細胞薬「SB623」の共同開発及びライセンス契約の解消についての追加説明（Q&A）
2019/12/16
- 2019年12月13日付け第３四半期決算短信及び再生細胞薬「SB623」の共同開発及びライセンス契約の解消についての追加説明
2019/12/13
- Notice Concerning Revisions to Consolidated Financial Forecasts for the Fiscal Year Ending January 31, 2020
2019/12/13
- SanBio and Sumitomo Dainippon Pharma Announce a Decision to Terminate a Joint Development and License Agreement
2019/12/13
- 北米での慢性期脳梗塞を対象とした再生細胞薬「SB623」の共同開発及びライセンス契約の解消について
2019/12/13
- Consolidated Financial Results for the Nine Months Ended October 31, 2019 [Japanese GAAP]
2019/11/29
- Announcement on Granting Stock Options (Share Acquisition Rights)
2019/09/20
- Agreement on Joint Research into SB623 for Indication of Retinal Disease
2019/09/19
- SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Traumatic Brain Injury
2019/09/19
- 慢性期外傷性脳損傷を対象にした再生細胞薬SB623が米国食品医薬品局の「RMAT」の対象品目に指定
2019/09/13
- 2020年１月期第２四半期累計期間の資金調達の総括について
2019/09/13
- Summary of Procurement of Funds in the First Half of the Fiscal Year Ending January 31, 2020
2019/09/13
- Notice Concerning Difference Between Consolidated Financial Forecasts and Actual Results for the First Half of the Fiscal Year Ending January 31, 2020
2019/09/13
- 営業外費用（為替差損）の計上に関するお知らせ
2019/09/13
- SB623外傷性脳損傷を対象にした第２相試験（STEMTRA試験）結果が2019 World Federation of Neurosurgical Societies Special World Congressにて発表について
2019/09/13
- Notice of Posting of Non-Operating Expenses (Foreign Exchange Losses)
2019/09/13
- SanBio announced the results of the Phase 2 STEMTRA trial at 2019 World Federation of Neurosurgical Societies Special World Congress
2019/09/13
- Consolidated Financial Results for the Six Months Ended July 31, 2019 [Japanese GAAP]
2019/08/30
- SanBio Announced the results of the Phase 2 STEMTRA trial of SB623 was presented at the Military Health System Research Symposium 2019
2019/08/30
- SB623外傷性脳損傷を対象にした第２相試験（STEMTRA試験）結果がMilitary Health System Research Symposium 2019にて発表について
2019/08/16
- [Delayed]Basic Agreement for Commercial Distribution with Suzuken Co., Ltd. and Start of Development Related to Patient Support System